Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies

被引：0
|
作者：
Laiyi Chua
Stuart Friedrich
Xin Cindy Zhang
机构：
[1] Eli Lilly and Company,Global PK/PD and Pharmacometrics
来源：
Clinical Pharmacokinetics | 2023年 / 62卷 / 10期
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1479 / 1491
页数：12
相关论文
共 50 条
  • [31] REDUCTION IN INFLAMMATORY BIOMARKERS IN A PHASE 2 STUDY OF MIRIKIZUMAB IN THE TREATMENT OF PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS
    Sandborn, William J.
    Sands, Bruce E.
    Kobayashi, Taku
    Tuttle, Jay
    Schmitz, Jochen
    Durante, Michael
    Higgs, Richard E.
    Canavan, James
    Siegel, Robert
    Ferrante, Marc
    GASTROENTEROLOGY, 2019, 156 (06) : S1094 - S1095
  • [32] The Effect of Mirikizumab on Fecal Calprotectin and C-Reactive Protein in Phase 3 Studies of Patients With Moderately-to-Severely Active Ulcerative Colitis
    Siegmund, Britta
    Sands, Bruce E.
    Samaan, Karen
    Li, Xingyuan
    Morris, Nathan
    Gibble, Theresa Hunter
    Redondo, Isabel
    Lissoos, Trevor
    D'Haens, Geert
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S543 - S544
  • [33] Extended induction response over time in patients with moderately-to-severely active Ulcerative Colitis treated with mirikizumab in the LUCENT-1 and-2 trials
    Rubin, D. T.
    Charabaty, A.
    Jairath, V.
    Walter, J.
    McGinnis, K.
    Moses, R.
    Maier, S.
    Escobar, R.
    Baygani, S.
    Zaremba-Pechmann, L.
    Kobayashi, T.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1641 - I1642
  • [34] EXTENDED INDUCTION RESPONSE OVER TIME IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB IN THE LUCENT-1 AND-2 TRIALS
    Rubin, David T.
    Charabaty, Aline
    Jairath, Vipul
    Walter, James
    McGinnis, Kim
    Moses, Richard
    Maier, Sebastian
    Escobar, Rodrigo
    Baygani, Simin
    Zaremba-Pechmann, Liliana
    Kobayashi, Taku
    GASTROENTEROLOGY, 2024, 166 (05) : S821 - S821
  • [35] PK, EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 SHINE-1 STUDY
    Kaplan, Jess
    Bousvaros, Athos
    Turner, Dan
    Dubinsky, Marla C.
    Komocsar, Wendy
    Larkin, Amy E.
    Johns, Jordan
    Zhang, Xin
    Little, Cheryl A.
    Crandall, Wallace
    Arora, Vipin
    Hyams, Jeffrey S.
    GASTROENTEROLOGY, 2023, 164 (06) : S169 - S169
  • [36] Sustained Improvement in Inflammatory Bowel Disease Questionnaire Outcomes in Moderately to Severely Active Ulcerative Colitis With Continued Mirikizumab Treatment in Phase 3 LUCENT-3 Study
    Sands, Bruce E.
    Feagan, Brian G.
    Armuzzi, Alessandro
    McGinnis, Kim
    Lynch, Keisa
    Gibble, Theresa Hunter
    Johns, Jordan
    Siegel, Corey A.
    Jairath, Vipul
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S812 - S813
  • [37] CORTICOSTEROID-SPARING EFFECT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB MAINTENANCE THERAPY
    Laharie, D.
    Siegel, C. A.
    Samaan, K.
    Fisher, D. A.
    Morris, N.
    Redondo, I.
    Dulai, P. S.
    Jairath, V.
    Gisbert, J. P.
    Matsuoka, K.
    Orlando, A.
    DIGESTIVE AND LIVER DISEASE, 2024, 56 : S163 - S164
  • [38] SUSTAINED IMPROVEMENT IN INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE OUTCOMES IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WITH CONTINUED MIRIKIZUMAB TREATMENT IN PHASE 3 LUCENT-3 STUDY
    Sands, B. E.
    Feagan, B. G.
    Armuzzi, A.
    Mcginnis, K.
    Lynch, K.
    Gibble, Hunter T.
    Johns, J.
    Siegel, C. A.
    Jairath, V.
    Asaro, J.
    DIGESTIVE AND LIVER DISEASE, 2024, 56 : S166 - S166
  • [39] EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS: PHASE 3 LUCENT-1 STUDY RESULTS
    D'Haens, Geert
    Kobayashi, Taku
    Morris, Nathan
    Lissoos, Trevor
    Hoover, Amy
    Li, Xingyuan
    Arora, Vipin
    Milch, Catherine
    Sandborn, William J.
    Sands, Bruce E.
    Irving, Peter
    GUT, 2022, 71 : A16 - A17
  • [40] Association of Bowel Urgency With Quality-of-Life Measures in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From Phase 3 LUCENT-1 (Induction) and LUCENT-2 (Maintenance) Studies
    Long, Millie D.
    Schreiber, Stefan
    Hibi, Toshifumi
    Gibble, Theresa Hunter
    Fisher, Deborah A.
    Park, Gina
    Moses, Richard E.
    Higgins, Peter D. R.
    Lindsay, James O.
    Lee, Scott D.
    Escobar, Rodrigo
    Jairath, Vipul
    CROHNS & COLITIS 360, 2024, 6 (01)
12345